文献速递肝肾功能剂量调整治疗药物监测与药物基因组学药物不良反应与药物警戒

超重和肥胖成人患者利奈唑胺群体药代动力学及给药考量

Population Pharmacokinetics and Dosing Considerations for the Use of Linezolid in Overweight and Obese Adult Patients.
PubMed 文献 · Clin Pharmacokinet · 2018-01-01

该回顾性队列研究纳入112例超重或肥胖住院患者,构建利奈唑胺群体药代动力学模型并进行蒙特卡洛模拟。结果显示,估算肌酐清除率(CrCLCKD-EPI)是唯一改善模型拟合的协变量。剂量调整应基于CrCLCKD-EPI而非体型指标,部分患者需治疗药物监测。

要点

  • 利奈唑胺剂量调整应基于CrCLCKD-EPI,而非体重或体型描述符。
  • CrCLCKD-EPI < 130 mL/min/1.73 m²的凝固酶阴性葡萄球菌感染患者,450 mg q12h可能最优。
  • CrCLCKD-EPI ≥ 60 mL/min/1.73 m²者,450 mg q8h可能最优;600 mg q8h因血小板减少风险不推荐。

核心结论

  • 超重和肥胖成人患者的利奈唑胺剂量调整应基于CrCLCKD-EPI估算值,而非体型指标。

研究设计与样本

  • 回顾性队列研究,纳入112例超重或肥胖住院患者,共352个谷浓度和293个峰浓度。
  • 采用群体药代动力学建模和蒙特卡洛模拟评估PTA。

主要发现

  • 最终混合饱和模型可解释88%的药物浓度随时间变异。
  • CrCLCKD-EPI是唯一改善模型拟合的协变量。

关键数值与推荐

  • 药效学靶值为AUC24/MIC > 100。
  • 最大允许剂量定义为谷浓度 > 8.06 mg/L(与血小板减少相关)概率 ≤ 25%的剂量。
  • CrCLCKD-EPI < 130 mL/min/1.73 m²且为凝固酶阴性葡萄球菌感染时,450 mg q12h可能最优。
  • CrCLCKD-EPI ≥ 60 mL/min/1.73 m²时,450 mg q8h可能最优。
  • 600 mg q8h因血小板减少风险不可接受,不推荐。

临床怎么用

  • 根据CrCLCKD-EPI估算值调整利奈唑胺剂量,无需依据体重。
  • CrCLCKD-EPI ≥ 130 mL/min/1.73 m²和/或合并使用P-糖蛋白调节剂者需进行治疗药物监测。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Linezolid is an anti-Gram-positive antimicrobial agent used at a fixed dose of 600 mg every 12 h. OBJECTIVES: The objective of this study was to assess the population pharmacokinetics and pharmacodynamics of linezolid in a retrospective cohort of overweight and obese hospitalized patients. PATIENTS AND METHODS: Population pharmacokinetic and Monte Carlo simulations were conducted to assess the probability of target attainment (PTA) of an area under the concentration-time curve from time zero to 24 h (AUC24)/minimum inhibitory concentration (MIC) ratio > 100, defined as the pharmacodynamic target of efficacy, with incremental candidate dosages. Maximum permissible doses were defined as those causing a ≤ 25% of probability of a linezolid trough of > 8.06 mg/L, associated with thrombocytopenia. The cumulative fraction of response was calculated for the permissible linezolid doses by testing the PTA against the MIC distributions of a large collection of Staphylococci and Enterococci. RESULTS: A total of 352 trough (minimum) and 293 peak (maximum) linezolid concentrations from 112 patients were included. The final mixed-saturative model accounted for 88% of drug concentrations variability over time, and estimated creatinine clearance [by means of the Chronic Kidney Diseases Epidemiology formula (CrCLCKD-EPI)] was the only covariate that improved the model fit. Dose reduction to 450 mg every 12 h may be optimal for patients with coagulase-negative staphylococcal infections and a CrCLCKD-EPI < 130 mL/min/1.73 m2. Dose escalation to 450 mg every 8 h may be optimal for patients with a CrCLCKD-EPI ≥ 60 mL/min/1.73 m2. Escalation to 600 mg every 8 h should not be recommended due to an unacceptable high risk of thrombocytopenia. Patients with CrCLCKD-EPI ≥ 130 mL/min/1.73 m2 and/or co-medication with P-glycoprotein modulators require therapeutic drug monitoring to optimize linezolid doses. CONCLUSIONS: Dosage adjustments of linezolid in this population should be based on CrCLCKD-EPI estimates, rather than on body size descriptors.

来源:Clin Pharmacokinet,查看原文。版权归原作者所有。

引用

  1. Cojutti P, Pai MP, Pea F, et al. Population Pharmacokinetics and Dosing Considerations for the Use of Linezolid in Overweight and Obese Adult Patients. Clin Pharmacokinet. 2018. PMID: 29080937. doi:10.1007/s40262-017-0606-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。